Chronic, non healing wounds are
a major public health problem requiring innovative treatments. The
long term objective of this application is to develop novel wound
care products designed to heal chronic wounds. To achieve this goal,
drug delivery technology developed by Biomerix, Inc. will be partnered
with unique tissue engineered models of human wound healing developed
by Dr. Jonathan Garlick. The proposed research is designed to determine
the therapeutic efficacy of novel, nitric oxide delivery devices
(NO CO FOAM) in engineered models of human wound repair. The specific
aims of this proposal are to determine parameters of biological
response when NO CO FOAM is used as a wound dressing in two wound
healing models: 1 In vitro, organotypic model and 2 In vivo, transplantation
model. Building on Dr. Garlick's expertise, these studies will provide
opportunities for new product commercialization in a way that would
not otherwise be possible. This unique platform technology will
allow Biomerix to greatly accelerate their development of this and
other wound care products that will provide a strong intellectual
property position leading to their dramatic growth. This award will
be a critical first step in laying the groundwork for Biomerix to
exploit future opportunities in the billion dollar wound care market. |
